Background Programmed death 1 (PD-1) inhibitors are frequently associated with thyroid-related adverse events (TAEs), but many aspects remain unclear. This study aims to evaluate the incidence and characteristics of such events and to find any predictive factor for its development. Methods We retrospectively analysed data from patients with advanced solid tumours (non-small-cell lung carcinoma, renal cell carcinoma, metastatic melanoma) treated with PD-1 inhibitors (nivolumab, pembrolizumab) in Oncology Unit B, Policlinico Umberto I of Rome, from June 2015 to December 2018. All patients underwent baseline thyroid function evaluations repeated monthly. Results The cohort consisted of 126 patients (66.7% male, mean age 66.4 +/- 9.7 years). One hundred and seven received nivolumab and 19 pembrolizumab. Twenty-three per cent of patients experienced TAEs (mainly CTCAE grade 1), with hypothyroidism in 15.1% (subclinical: 11.9%, overt: 3.2%) and hyperthyroidism in 8.0% (subclinical: 4.8%, overt: 3.2%). Median time to TAE onset was 8.7 +/- 6.8 weeks (10.4 +/- 7.6 weeks for hypothyroidism, 5.4 +/- 3.0 weeks for hyperthyroidism). Most TAEs (89.7%) appeared within the first 3 months, none after 8 months. Most hypothyroid patients (63.2%) had previously been treated with a tyrosine kinase inhibitor (TKI). Logistic regression analysis showed that pretreatment with a TKI was a major predisposing factor for the development of hypothyroidism (OR 9.2, 95% CI: 1.4-59.9, P = .020). Conclusions TAEs are common during anti-PD-1 therapy and usually occur within the first 3 months of treatment. This is the first study evaluating the impact of previous oncologic therapies on TAEs, identifying TKI as a major risk factor for the development of hypothyroidism in patients treated with anti-PD-1.

Thyroid disorders in programmed death 1 inhibitor-treated patients: Is previous therapy with tyrosine kinase inhibitors a predisposing factor? / Sbardella, Emilia; Tenuta, Marta; Sirgiovanni, Grazia; Gianfrilli, Daniele; Pozza, Carlotta; Venneri, Mary Anna; Cortesi, Enrico; Marchetti, Paolo; Lenzi, Andrea; Gelibter, Alain J; Isidori, Andrea M. - In: CLINICAL ENDOCRINOLOGY. - ISSN 0300-0664. - 92:3(2020), pp. 258-265. [10.1111/cen.14135]

Thyroid disorders in programmed death 1 inhibitor-treated patients: Is previous therapy with tyrosine kinase inhibitors a predisposing factor?

Sbardella, Emilia
Primo
;
Tenuta, Marta
Secondo
;
Sirgiovanni, Grazia;Gianfrilli, Daniele;Pozza, Carlotta;Venneri, Mary Anna;Cortesi, Enrico;Marchetti, Paolo;Lenzi, Andrea;Gelibter, Alain J
Penultimo
;
Isidori, Andrea M
Ultimo
2020

Abstract

Background Programmed death 1 (PD-1) inhibitors are frequently associated with thyroid-related adverse events (TAEs), but many aspects remain unclear. This study aims to evaluate the incidence and characteristics of such events and to find any predictive factor for its development. Methods We retrospectively analysed data from patients with advanced solid tumours (non-small-cell lung carcinoma, renal cell carcinoma, metastatic melanoma) treated with PD-1 inhibitors (nivolumab, pembrolizumab) in Oncology Unit B, Policlinico Umberto I of Rome, from June 2015 to December 2018. All patients underwent baseline thyroid function evaluations repeated monthly. Results The cohort consisted of 126 patients (66.7% male, mean age 66.4 +/- 9.7 years). One hundred and seven received nivolumab and 19 pembrolizumab. Twenty-three per cent of patients experienced TAEs (mainly CTCAE grade 1), with hypothyroidism in 15.1% (subclinical: 11.9%, overt: 3.2%) and hyperthyroidism in 8.0% (subclinical: 4.8%, overt: 3.2%). Median time to TAE onset was 8.7 +/- 6.8 weeks (10.4 +/- 7.6 weeks for hypothyroidism, 5.4 +/- 3.0 weeks for hyperthyroidism). Most TAEs (89.7%) appeared within the first 3 months, none after 8 months. Most hypothyroid patients (63.2%) had previously been treated with a tyrosine kinase inhibitor (TKI). Logistic regression analysis showed that pretreatment with a TKI was a major predisposing factor for the development of hypothyroidism (OR 9.2, 95% CI: 1.4-59.9, P = .020). Conclusions TAEs are common during anti-PD-1 therapy and usually occur within the first 3 months of treatment. This is the first study evaluating the impact of previous oncologic therapies on TAEs, identifying TKI as a major risk factor for the development of hypothyroidism in patients treated with anti-PD-1.
2020
PD-1 inhibitor; hypothyroidism; immune checkpoint inhibitor (ICI); thyroid; tyrosine kinase inhibitor
01 Pubblicazione su rivista::01a Articolo in rivista
Thyroid disorders in programmed death 1 inhibitor-treated patients: Is previous therapy with tyrosine kinase inhibitors a predisposing factor? / Sbardella, Emilia; Tenuta, Marta; Sirgiovanni, Grazia; Gianfrilli, Daniele; Pozza, Carlotta; Venneri, Mary Anna; Cortesi, Enrico; Marchetti, Paolo; Lenzi, Andrea; Gelibter, Alain J; Isidori, Andrea M. - In: CLINICAL ENDOCRINOLOGY. - ISSN 0300-0664. - 92:3(2020), pp. 258-265. [10.1111/cen.14135]
File allegati a questo prodotto
File Dimensione Formato  
Sbardella_postprint_Thyroid-disorders_2019.pdf

solo gestori archivio

Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 1.53 MB
Formato Adobe PDF
1.53 MB Adobe PDF   Contatta l'autore
Sbardella_Thyroid disorders_2020.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 368.82 kB
Formato Adobe PDF
368.82 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1347598
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 17
  • ???jsp.display-item.citation.isi??? 18
social impact